Barclays’s BioTelemetry, Inc. BEAT Stock Holding History

Barclays’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-77,000	Closed	-$3.71M	–	7506
2019 Q2	$3.71M	Buy	77,000 +75,000	+3,750%	+$3.94M	﹤0.01%	2164
2019 Q1	$125K	Sell	2,000 -1,000	-33%	-$68.7K	﹤0.01%	5194
2018 Q4	$179K	Buy	3,000 +1,100	+58%	+$66K	﹤0.01%	4652
2018 Q3	$122K	Sell	1,900 -500	-21%	-$27.9K	﹤0.01%	5388
2018 Q2	$108K	Buy	2,400 +2,200	+1,100%	+$87.7K	﹤0.01%	5196
2018 Q1	$6K	Buy	200 +100	+100%	+$3.29K	﹤0.01%	6776
2017 Q4	$3K	Buy	+100	New	+$2.9K	﹤0.01%	6766

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

Barclays's BEAT Position: Q1 2021 in Review

Barclays sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 224,418 shares — an estimated $16.2M sold.

Barclays first reported a position in BEAT in Q2 2013 and held it in 30 quarters. The position peaked at $16.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

Barclays reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
Barclays sold 224,418 BioTelemetry, Inc. shares in Q1 2021, an estimated $16.2M.
Barclays first reported a position in BioTelemetry, Inc. in Q2 2013 and held it in 30 quarters.
Barclays's BioTelemetry, Inc. position peaked at $16.2M in Q4 2020.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Barclays's 13F filing for Q1 2021, filed 13 May 2021.